Literature DB >> 10975678

Combining radiation therapy with interleukin-3 gene immunotherapy.

C S Chiang1, J H Hong, Y C Wu, W H McBride, G J Dougherty.   

Abstract

The goal of this study was to explore immunological strategies to increase local and systemic tumor control in patients receiving radiation therapy. In previous studies, interleukin-3 (IL-3) gene expression within murine tumors was shown to increase their response to irradiation through immune mechanisms. In this study, the efficacy of systemically administered IL-3 gene-transduced irradiated tumor cell vaccines was tested for their ability to augment radiation responses against established immunogenic (FSAR) and nonimmunogenic (FSAN) tumors. Vaccines of irradiated FSAR/FSAN or FSAN-JmIL-3/FSAR-JmIL-3 cells were given intraperitoneally just before and after local irradiation of parental tumors with diameters of 8 mm, as well as in two booster doses. The IL-3 gene-transduced tumor cell vaccines were more effective than the parental vaccines at delaying tumor growth after irradiation, although no complete cures resulted. Responses were largely specific to the tumor type, indicating that tumor-specific immunity was enhanced by IL-3 vaccine administration. When the experiment was repeated in the C3H/HeJ mice, which are deficient in tumor necrosis factor-alpha production, the vaccines were still effective, but less so than in C3H/HeN mice. Systemic IL-3 vaccine treatment increased intratumoral levels of intercellular adhesion molecule-1, Mac-1, EB22/5.3, tumor necrosis factor-alpha, and IL-1 mRNA in irradiated tumors, indicating that cellular infiltration was part of the response. The study demonstrates that local radiation therapy can enhance the efficacy of genetically altered vaccine-based immunotherapy for cancer by decreasing tumor burden. At the same time, tumor cell vaccines may improve the cure rate of local radiation therapy by eliminating residual cancer cells. Although less effective than intratumoral gene expression, administration of IL-3 gene-transduced tumor cell vaccines is clinically a more feasible strategy that may be useful in situations in which the tumor load is small.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10975678     DOI: 10.1038/sj.cgt.7700217

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  9 in total

1.  T-cell responses to survivin in cancer patients undergoing radiation therapy.

Authors:  Dörthe Schaue; Begonya Comin-Anduix; Antoni Ribas; Li Zhang; Lee Goodglick; James W Sayre; Annelies Debucquoy; Karin Haustermans; William H McBride
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

Review 2.  Combining immunotherapy and radiotherapy in lung cancer.

Authors:  Neeraj Bhalla; Rachel Brooker; Michael Brada
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 3.  Chapter seven--Cancer treatment with gene therapy and radiation therapy.

Authors:  Sergey A Kaliberov; Donald J Buchsbaum
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

Review 4.  Combining radiotherapy and immunotherapy: a revived partnership.

Authors:  Sandra Demaria; Nina Bhardwaj; William H McBride; Silvia C Formenti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-11-01       Impact factor: 7.038

Review 5.  Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities.

Authors:  Ravi B Patel; Claire C Baniel; Raghava N Sriramaneni; Kristin Bradley; Stephanie Markovina; Zachary S Morris
Journal:  Brachytherapy       Date:  2018-08-02       Impact factor: 2.362

Review 6.  Radiation as immunomodulator: implications for dendritic cell-based immunotherapy.

Authors:  Robert E Roses; Jashodeep Datta; Brian J Czerniecki
Journal:  Radiat Res       Date:  2014-07-03       Impact factor: 2.841

7.  Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4+ effector T cell infiltration into murine pancreatic tumors.

Authors:  Neeha Zaidi; Sergio A Quezada; Janelle M Y Kuroiwa; Li Zhang; Elizabeth M Jaffee; Ralph M Steinman; Bei Wang
Journal:  Ann N Y Acad Sci       Date:  2019-04-04       Impact factor: 6.499

8.  Granzyme B PET imaging of immune-mediated tumor killing as a tool for understanding immunotherapy response.

Authors:  Thomas LaSalle; Emily E Austin; Grant Rigney; Eric Wehrenberg-Klee; Sarah Nesti; Benjamin Larimer; Umar Mahmood
Journal:  J Immunother Cancer       Date:  2020-05       Impact factor: 13.751

Review 9.  Immunotherapy as sensitizer for local radiotherapy.

Authors:  Ben G L Vanneste; Evert J Van Limbergen; Ludwig Dubois; Iryna V Samarska; L Wieten; M J B Aarts; T Marcelissen; Dirk De Ruysscher
Journal:  Oncoimmunology       Date:  2020-10-30       Impact factor: 8.110

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.